Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP and CFO | February 18, 2025 | February 19, 2025 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
| WATERS CORP /DE/WAT · Entity 3080 | Director | February 25, 2026 | February 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 18, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 225,808 |
Ending reported balance
After 2025-02-19 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2025-02-18 · Sale · Disposed 2,900 · Balance 247,248 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2025-02-18 · Sale · Disposed 14,630 · Balance 232,618 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2025-02-19 · Exercise / conversion · Acquired 18,533 · Balance 251,151 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 4 · 2025-02-19 · Exercise / conversion · Acquired 16,865 · Balance 268,016 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 5 · 2025-02-19 · Exercise / conversion · Acquired 15,642 · Balance 283,658 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 6 · 2025-02-19 · Exercise / conversion · Acquired 9,483 · Balance 293,141 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 7 · 2025-02-19 · Sale · Disposed 67,333 · Balance 225,808 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.09 · Expires 2028-02-15 | Direct | 31,285 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Exercise / conversion · Disposed 15,642 · Balance 31,285 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.12 · Expires 2029-02-21 | Direct | 37,934 |
Reported balance
After 2025-02-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-19 · Exercise / conversion · Disposed 9,483 · Balance 37,934 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.26 · Expires 2026-02-22 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-19 · Exercise / conversion · Disposed 16,865 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.55 · Expires 2027-02-28 | Direct | 37,067 |
Reported balance
After 2025-02-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-02-19 · Exercise / conversion · Disposed 18,533 · Balance 37,067 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F8: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F8: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,371 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 404 · Balance 1,371 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 681 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 681 · Balance 681 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
WATERS CORP /DE/
Report date February 25, 2026 · Filed February 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,355 |
Reported balance
After 2026-02-25 transaction · row 1
1 source rowRow 1 · 2026-02-25 · Grant · Acquired 23 · Balance 1,355 F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $319.44 · Expires 2036-02-25 | Direct | 57 |
Reported balance
After 2026-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-25 · Grant · Acquired 57 · Balance 57 F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027.
F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nuance Communications, Inc.
Report date March 04, 2022 · Filed March 04, 2022
Section 16 reporting ended · disclosed 2022-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-04 · Disposition to issuer · Disposed 4,519 · Balance 53,492 F1: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award. Row 2 · 2022-03-04 · Disposition to issuer · Disposed 53,492 · Balance 0 F2: On March 4, 2022, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the Merger), and each Company Share issued and outstanding at the effective time of the Merger was converted into the right to receive $56.00 in cash without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award.
F2: On March 4, 2022, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the Merger), and each Company Share issued and outstanding at the effective time of the Merger was converted into the right to receive $56.00 in cash without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 681 | $0.00 Strike: $499.86 | $0.00 |
DisclosureSEC source: 0001628280-26-044290 · wk-form4_1781813560.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 681 Underlying: Common Stock · 681 shares Expires 2036-06-17 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 404 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-044290 · wk-form4_1781813560.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,371 F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:13 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 57 | $0.00 Strike: $319.44 | $0.00 |
DisclosureSEC source: 0001000697-26-000073 · form4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57 Underlying: Common Stock · 57 shares Expires 2036-02-25 F2 · shares: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:13 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 23 | $0.00 | $0.00 |
DisclosureSEC source: 0001000697-26-000073 · form4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,355 F1 · shares: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:43 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 828 | $0.00 Strike: $381.96 | $0.00 |
DisclosureSEC source: 0001000697-26-000023 · form4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828 Underlying: Common Stock · 828 shares Expires 2036-01-02 F2 · shares: All of the shares of common stock underlying this stock option will vest and become exercisable on January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:43 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 307 | $0.00 | $0.00 |
DisclosureSEC source: 0001000697-26-000023 · form4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,332 F1 · shares: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on January 2, 2027. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 23:23 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,705 | $0.00 Strike: $302.17 | $0.00 |
DisclosureSEC source: 0001628280-25-038008 · wk-form4_1754436199.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,705 Underlying: Common Stock · 1,705 shares Expires 2035-08-01 F2 · derivative.exercise_date: The option vests as to 50% of the shares on the first anniversary of the date of grant (August 1, 2026) and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 23:23 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 967 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-038008 · wk-form4_1754436199.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 967 F1 · kind: Represents a grant of restricted stock units which vest as to 50% of the shares on each of August 1, 2026 and August 1, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,533 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · derivative · entry 11 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,067 Underlying: Common Stock · 18,533 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,865 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · derivative · entry 10 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,865 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,483 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,934 Underlying: Common Stock · 9,483 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,642 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,285 Underlying: Common Stock · 15,642 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 67,333 | $105.24 | $7,086,111.45 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · nonDerivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,808 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 9,483 | $40.12 | $380,457.96 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · nonDerivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 15,642 | $27.09 | $423,741.78 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,865 | $17.26 | $291,089.90 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 18,533 | $24.55 | $454,985.15 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 251,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 14,630 | $104.67 | $1,531,365.99 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,618 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,900 | $104.08 | $301,818.08 |
DisclosureSEC source: 0001225208-25-001969 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 11 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,584 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,217 | $106.11 | $235,245.87 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,148 Read SEC document |
| February 17, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 10 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,243 Underlying: Common Stock · 4,243 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,052 | $106.11 | $217,737.72 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,781 Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,725 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,110 | $106.11 | $223,892.10 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,590 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 23,031 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,031 Underlying: Common Stock · 23,031 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 8,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,950 Underlying: Common Stock · 8,950 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,087 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · derivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,087 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 15,087 | $105.07 | $1,585,135.27 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,451 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.778 to $105.28, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 15,087 | $16.31 | $246,068.97 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 3,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001788 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,963 Underlying: Common Stock · 3,654 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,767 | $105.77 | $186,895.59 |
DisclosureSEC source: 0001225208-25-001788 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,338 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001788 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 16,414 | $105.98 | $1,739,555.72 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,451 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 33,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 257,865 F1 · kind: On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 03, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 9,689 | $89.86 | $870,636.10 |
DisclosureSEC source: 0001225208-25-000201 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,921 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.52 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 17:53 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 818 | $0.00 Strike: $368.26 | $0.00 |
DisclosureSEC source: 0001127602-25-000633 · form4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818 Underlying: Common Stock · 818 shares Expires 2035-01-02 F2 · shares: Options vest in full on January 2, 2026. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 17:53 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 319 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000633 · form4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,025 F1 · shares: Represents shares of restricted stock which will vest in full on January 2, 2026. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 14,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000201 · doc4.xml · derivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,901 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 5,212 | $89.32 | $465,535.84 |
DisclosureSEC source: 0001225208-25-000201 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,610 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 14,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000201 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| May 23, 2024 Filed May 23, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 47,621 | $75.11 | $3,576,932.36 |
DisclosureSEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,921 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.86 to $75.48, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,863 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 10 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,600 Underlying: Common Stock · 16,863 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024. F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,086 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,087 Underlying: Common Stock · 15,086 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,863 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,865 Underlying: Common Stock · 16,863 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,642 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-24-006325 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,927 Underlying: Common Stock · 15,642 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 64,454 | $75.91 | $4,892,819.16 |
DisclosureSEC source: 0001225208-24-006325 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,542 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.512 to $76.22, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.